Especially the brainzaps are a issue for many; personally i have noted that amphetamine blocks them and that serotonine antagonists like mirtazepine make them significantly worse; ive long pondered about this issue but this will provide some insights.
The gabab agonism decreases glutamate; now here's the interesting part; amphetamine releases glutamate overwriting this decrease in glutamate and mirtazepine reduces glutamate trough 5HT2A antagonism wich is a glutamate releaser.
A intervention for this problem would either be downregulating GABAB however that may change its rewarding effects; or adding something that increases glutamate but that has excitoxiticy as issue.
After some thinking i came up with the idea of the addition of aniracetam; it releases glutamate while also blocking excitoxiticy.
Aniracetam also improves cognition and could counteract impairment caused by GHB.
Thats the post for the day; ive discovered alot the recent months i was away and beleive i may have a solution for many major problems; however skeptism is at its place; so slowly ill explain a idea to see ppl's results and that way really do what bluelight stands for; harm reduction.
The first in vivo effects of GHB were described in 1964 as hypothermic, hypnotic, anesthetic, and anti-convulsant, and without marked respiratory depression or toxicity (Laborit, 1964). Since that time, the mechanisms underlying many of these effects have been further examined and elucidated. For example, as one of the initial and continued therapeutic interests in GHB centered around its potential to induce specific stages of sleep, many early studies focused on examining the electroencephalographic (EEG) effects of GHB. GHB and GBL (at 50–200 mg/kg) produced EEG patterns similar to those observed during slow wave sleep and absence seizures in rats (Winters and Spooner, 1965; Godschalk et al., 1977). The dopaminergic and opioidergic systems were initially implicated in the EEG effects of GHB because the absence seizure-like activity of GHB was blocked or reversed by d-amphetamine and naloxone, respectively (Snead, 1978; Snead and Bearden, 1980). However, later studies showed that selective GABAB receptor antagonists attenuated GHB-induced changes in EEG activity and decreases in firing rate and burst activity of dopaminergic neurons (Snead, 1996; Erhardt et al., 1998). Thus, it is likely that GABAB receptor-mediated inhibition of neurotransmitter release by GHB and baclofen is responsible for the absence seizure-like activity of these two drugs (Banerjee and Snead, 1995). Indeed, 100 mg/kg GBL did not result in absence seizure-like activity in transgenic mice that lack functional GABAB receptors (Kaupmann et al., 2003). Moreover, the GHB antagonist, NCS-382 has not always antagonized the EEG effects of GHB or baclofen, suggesting that GHB binding sites do not play a substantial role in mediating these effects (Snead, 1996; Erhardt et al., 1998; Tremblay et al., 1998).
The gabab agonism decreases glutamate; now here's the interesting part; amphetamine releases glutamate overwriting this decrease in glutamate and mirtazepine reduces glutamate trough 5HT2A antagonism wich is a glutamate releaser.
A intervention for this problem would either be downregulating GABAB however that may change its rewarding effects; or adding something that increases glutamate but that has excitoxiticy as issue.
After some thinking i came up with the idea of the addition of aniracetam; it releases glutamate while also blocking excitoxiticy.
Aniracetam also improves cognition and could counteract impairment caused by GHB.
Thats the post for the day; ive discovered alot the recent months i was away and beleive i may have a solution for many major problems; however skeptism is at its place; so slowly ill explain a idea to see ppl's results and that way really do what bluelight stands for; harm reduction.
